Jazz Pharmaceuticals Welcomes Thomas Riga as Chief Business Officer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is thrilled to announce the appointment of Thomas Riga as its new Chief Business Officer, a role effective at the beginning of 2026. With over 25 years of rich experience in both commercial and operational domains, Riga is poised to drive impactful corporate strategies and initiatives.
Extensive Experience in the Pharmaceutical Industry
Before joining Jazz, Mr. Riga was instrumental during his tenure at Chimerix Inc., where he held the position of chief operating and commercial officer. His leadership was crucial during Chimerix's acquisition by Jazz, where he played a pivotal role in shaping the company’s corporate strategy. Under his guidance, the approval and launch of transformative therapies were realized, including a groundbreaking treatment for H3K27M-mutant diffuse midline glioma, which affects around 2,000 young patients annually in the United States.
Leadership Perspectives on Riga’s Appointment
Renee Gala, president and chief executive officer of Jazz Pharmaceuticals, expressed her enthusiasm regarding Riga’s appointment, highlighting his extensive track record in leading significant transactions within the industry. "Tom combines a passion for patient care with deep commercial knowledge and operational proficiency. His history of managing over $2 billion in business development deals in the recent past speaks volumes about his capabilities," she remarked. She also noted Riga's involvement in the introduction of Modeyso™ (dordaviprone), which addresses an ultra-rare, aggressive brain tumor commonly affecting young individuals.
Riga's Vision for Jazz Pharmaceuticals
Upon his appointment, Riga conveyed his excitement about taking on this critical role at Jazz. "I am honored to step into this position and have been continually impressed with Jazz's vision and leadership," he said. He sees a bright future where innovative transactions will leverage existing skills and strengths within the company, thereby enhancing shareholder value and significantly improving outcomes for patients in urgent need of effective therapies.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is dedicated to developing transformative and potentially life-saving medicines for serious diseases, often providing hope where few options exist. The company boasts a diverse portfolio that includes leading therapies for sleep disorders, epilepsy, and a growing array of cancer treatments. Guided by a patient-centered and research-focused philosophy, Jazz is committed to pioneering advancements across a robust development pipeline, particularly in oncology and neuroscience.
The global biopharma company is headquartered in Dublin, Ireland, with extensive operations, research, and manufacturing facilities spread across several countries, all aimed at providing better patient outcomes worldwide.
Frequently Asked Questions
Who is Thomas Riga?
Thomas Riga is the newly appointed Chief Business Officer of Jazz Pharmaceuticals, bringing over 25 years of pharmaceutical experience.
What role did Riga have before joining Jazz?
Before his current role, Thomas Riga served as Chief Operating and Commercial Officer at Chimerix Inc., where he played a key part in the company's acquisition by Jazz.
What are some achievements of Riga in the pharmaceutical field?
Riga has a significant record in managing strategic transactions and has been instrumental in launching therapies that address serious medical conditions, including treatments for aggressive brain tumors.
What is Jazz Pharmaceuticals' focus?
Jazz Pharmaceuticals focuses on developing innovative therapies for patients with serious diseases, emphasizing areas with limited treatment options, such as oncology and neuroscience.
Where is Jazz Pharmaceuticals headquartered?
Jazz Pharmaceuticals is headquartered in Dublin, Ireland, with a global presence in research, manufacturing, and patient care.
